| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H27FO5 |
| Molecular Weight | 378.4345 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C
InChI
InChIKey=MYYIMZRZXIQBGI-HVIRSNARSA-N
InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1
| Molecular Formula | C21H27FO5 |
| Molecular Weight | 378.4345 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Fluprednisolone is glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated (hypersensitivity dermatoses, contact dermatitis, pemphigus, pemphigoid, lupus erythematosus, neoplasia etc), except adrenal deficiency states.
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
A dose of 3 mg per kilogram in dogs for a period of two weeks produced no toxic effects.
Route of Administration:
Oral
Lymphosarcoma P1798 cells was treated with 9FP (Fluprednisolone). Ribonuclease activity of the cells was measured after incubation with 0.1 mkg/ml 9FP (Fluprednisolone) for various time periods (from 6 to 48 h). Cells also develop increased acid ribonuclease activity after incubation with 9FP (Fluprednisolone) in vitro.
